Pfizer and partners pull plug on bapineuzumab for Alzheimer's after second Phase III failure
12:35 EDT 7 Aug 2012 | SCRIP
Pfizer, Janssen and Elan are to end all clinical trials with intravenous bapineuzumab in the treatment of mild-to-moderate Alzheimer's disease. The decision came after the monoclonal antibody, which targets amyloid-beta protein, did not.....
Original Article: Pfizer and partners pull plug on bapineuzumab for Alzheimer's after second Phase III failure
More From BioPortfolio on "Pfizer and partners pull plug on bapineuzumab for Alzheimer's after second Phase III failure"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
